ResMed CFO Executes Stock Sale Under Rule 10b5-1 Plan

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has provided an update.

ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a transaction involving the sale of 1,000 shares of ResMed common stock under a pre-established Rule 10b5-1 trading plan. This transaction, executed on June 2, 2025, reflects the CFO’s adherence to regulatory compliance while managing personal stock holdings. Such transactions are part of routine financial management and may not directly impact the company’s operational strategies or market position.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. operates in the healthcare industry, specializing in the development and manufacturing of equipment related to sleep disorders and respiratory care. The company is known for its innovative solutions that cater to patients with sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Average Trading Volume: 1,317,793

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$55.21B

Learn more about RMD stock on TipRanks’ Stock Analysis page.